FIRST WAVE BIOPHARMA (FWBI) Stock Price & Overview

NASDAQ:FWBI • US33749P4081

2.96 USD
+0.13 (+4.59%)
Last: May 16, 2024, 08:00 PM

The current stock price of FWBI is 2.96 USD. Today FWBI is up by 4.59%. In the past month the price increased by 4.23%. In the past year, price decreased by -93.21%.

FWBI Key Statistics

52-Week Range2.3335 - 59.998
Current FWBI stock price positioned within its 52-week range.
1-Month Range2.3335 - 3.3999
Current FWBI stock price positioned within its 1-month range.
Market Cap
4.621M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-88.75
Dividend Yield
N/A

FWBI Stock Performance

Today
+4.59%
1 Week
+4.96%
1 Month
+4.23%
3 Months
-43.40%
Longer-term
6 Months -44.28%
1 Year -93.21%
2 Years -99.80%
3 Years N/A
5 Years N/A
10 Years N/A

FWBI Stock Chart

FIRST WAVE BIOPHARMA / FWBI Daily stock chart

FWBI Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to FWBI. When comparing the yearly performance of all stocks, FWBI is a bad performer in the overall market: 98.3% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating
FWBI Full Technical Analysis Report

FWBI Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to FWBI. FWBI may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
FWBI Full Fundamental Analysis Report

FWBI Earnings

Next Earnings DateAug 14, 2024
Last Earnings DateMay 12, 2024
PeriodQ4 / 2023
EPS Reported-$5.35
Revenue Reported
EPS Surprise -29.99%
Revenue Surprise %
FWBI Earnings History

FWBI Forecast & Estimates

8 analysts have analysed FWBI and the average price target is 36.72 USD. This implies a price increase of 1140.54% is expected in the next year compared to the current price of 2.96.


Analysts
Analysts80
Price Target36.72 (1140.54%)
EPS Next Y95.87%
Revenue Next YearN/A
FWBI Forecast & Estimates

FWBI Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

FWBI Financial Highlights

Over the last trailing twelve months FWBI reported a non-GAAP Earnings per Share(EPS) of -88.75. The EPS increased by 75.5% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-16.10M
Industry RankSector Rank
PM (TTM) N/A
ROA -233.87%
ROE -446.8%
Debt/Equity 0.17
Chartmill High Growth Momentum
EPS Q2Q%97.18%
Sales Q2Q%N/A
EPS 1Y (TTM)75.5%
Revenue 1Y (TTM)N/A
FWBI financials

FWBI Ownership

Ownership
Inst Owners5.98%
Shares1.56M
Float1.87M
Ins Owners10.98%
Short Float %N/A
Short RatioN/A
FWBI Ownership

FWBI Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC15.3402.17B
AMGN AMGEN INC16.45203.213B
GILD GILEAD SCIENCES INC16.81182.029B
VRTX VERTEX PHARMACEUTICALS INC25.75117.075B
REGN REGENERON PHARMACEUTICALS16.5182.631B
ALNY ALNYLAM PHARMACEUTICALS INC43.2142.915B
INSM INSMED INC N/A30.852B
NTRA NATERA INC N/A29.086B
BIIB BIOGEN INC11.7227.626B
UTHR UNITED THERAPEUTICS CORP17.9423.193B
MRNA MODERNA INC N/A22.014B
EXAS EXACT SCIENCES CORP340.0819.797B
RVMD REVOLUTION MEDICINES INC N/A19.775B

About FWBI

Company Profile

FWBI logo image First Wave BioPharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boca Raton, Florida and currently employs 10 full-time employees. The company went IPO on 2016-10-11. First Wave BioPharma, Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. The company is focused on developing its pipeline of gut-restricted GI clinical drug candidates, including the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, and niclosamide, which is an oral small molecule with anti-viral and anti-inflammatory properties. Its adrulipase programs are focused on the development of an oral, non-systemic, biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company is advancing two separate Phase 2 clinical programs of its niclosamide formulations, including FW-COV for Severe Acute Respiratory Syndrome Coronavirus 2 GI infections, and FW-UP for ulcerative proctitis and ulcerative proctosigmoiditis.

Company Info

IPO: 2016-10-11

FIRST WAVE BIOPHARMA

777 Yamato Road, Suite 502

Boca Raton FLORIDA US

CEO: James Sapirstein

Employees: 10

FWBI Company Website

Phone: 15615897020

FIRST WAVE BIOPHARMA / FWBI FAQ

What does FIRST WAVE BIOPHARMA do?

First Wave BioPharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boca Raton, Florida and currently employs 10 full-time employees. The company went IPO on 2016-10-11. First Wave BioPharma, Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. The company is focused on developing its pipeline of gut-restricted GI clinical drug candidates, including the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, and niclosamide, which is an oral small molecule with anti-viral and anti-inflammatory properties. Its adrulipase programs are focused on the development of an oral, non-systemic, biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company is advancing two separate Phase 2 clinical programs of its niclosamide formulations, including FW-COV for Severe Acute Respiratory Syndrome Coronavirus 2 GI infections, and FW-UP for ulcerative proctitis and ulcerative proctosigmoiditis.


Can you provide the latest stock price for FIRST WAVE BIOPHARMA?

The current stock price of FWBI is 2.96 USD. The price increased by 4.59% in the last trading session.


Does FWBI stock pay dividends?

FWBI does not pay a dividend.


What is the ChartMill rating of FIRST WAVE BIOPHARMA stock?

FWBI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


What sector and industry does FIRST WAVE BIOPHARMA belong to?

FIRST WAVE BIOPHARMA (FWBI) operates in the Health Care sector and the Biotechnology industry.


Can you provide the market cap for FIRST WAVE BIOPHARMA?

FIRST WAVE BIOPHARMA (FWBI) has a market capitalization of 4.62M USD. This makes FWBI a Nano Cap stock.